



3762

H 4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. Rigdon Lentz

Serial No.: 09/316,226

Art Unit: 3762

Filed: May 21, 1999

Examiner: Not Yet Assigned

For: *METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS*

Assistant Commissioner for Patents  
Washington, D.C. 20231

GROUP 3600

SEP 02 1999

RECEIVED

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits an Information Disclosure Statement, including one (1) page of Form PTO-1449. All of the documents cited below were cited by or submitted to the Patent Office in Application Serial No. 09/083,307, filed May 22, 1998, to which the present application claims priority. Pursuant to 37 C.F.R. §1.98(d), Applicants are not enclosing copies of these publications. Copies will be provided upon request, however.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 01-2507.

RECEIVED  
SEP - 3 1999  
3:00 MAIL ROOM

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,708,713	11-24-1987	Lentz	604/005
5,135,919	08-04-1992	Folkman, et al.	514/056
5,147,638	09-15-1992	Esmon, et al.	424/085.8
5,290,807	03-01-1994	Folkman, et al.	514/475

U.S.S.N.: 09/316,226  
Filed: May 21, 1999  
INFORMATION DISCLOSURE STATEMENT

5,523,096	06-04-1996	Okarma, et al.	424/489
5,629,327	05-13-1997	D'Amato	514/323
5,639,725	06-17-1997	O'Reilly, et al.	514/012
5,698,586	12-16-1997	Kishimoto, et al.	514/475
5,712,291	01-27-1998	D'Amato	514/323
5,713,491	02-03-1998	Hughes, et al.	222/129
5,716,981	02-10-1998	Hunter, et al.	514/449
5,733,876	03-31-1998	O'Reilly, et al.	514/0
5,861,483	01-19-1999	Wolpe	530/385

### Publications

CHEN, et al., "Soluble TNF- Receptors are constitutively shed and downregulate adhesion molecule expression in malignant gliomas," *J. Neuropathol. Exp. Neurol.* 56(5):541-550 (1997).

COLMAN, et al., Hemostasis and Thrombosis: Basic Principles and Clinical Practice (2nd Ed.), p. 263, J.B.Lippincott:Philadelphia, PA, 1987.

JABLONSKA & PEITRUSKA, "Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients," *Arch Immunol Ther Exp (Warsz)*. 45(5-6):449-53 (1997).

MATSCHINER, et al., Current Advances in Vitamin K Research, pp. 135-140, (John W. Suttie, ed.) Elsevier Science Publishing Co., Inc., 1988.

U.S.S.N.: 09/316,226  
Filed: May 21, 1999  
INFORMATION DISCLOSURE STATEMENT

### Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst  
Reg. No. 31,284

Dated: August 27, 1999


ARNALL GOLDEN & GREGORY, LLP  
2800 One Atlantic Center  
1201 W. Peachtree Street  
Atlanta, Georgia 30309-3450  
(404) 873-8794  
(404) 873-8795 (fax)

U.S.S.N.: 09/316,226  
Filed: May 21, 1999  
INFORMATION DISCLOSURE STATEMENT

**Certificate of Mailing under 37 CFR 1.8(a)**

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: August 27, 1999

  
Julie A. Tennyson